Commitments and Contingencies (Details)					12 Months Ended
		Dec. 10, 2015 USD ($) shares	Dec. 20, 2013 $ / shares	Dec. 10, 2013 USD ($) $ / shares	Dec. 31, 2015 USD ($) Lawsuit shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($)	Feb. 26, 2016 Motion	Jun. 02, 2015 shares
Operating leases, future cash payments [Abstract]
2016	[1]				$ 318,000
2017	[1]				383,000
2018	[1]				363,000
2019	[1]				278,000
2020	[1]				59,000
Thereafter	[1]				0
Total	[1]				1,401,000
Lease expense					351,075	$ 335,991	$ 315,134
Employment agreements, future cash payments [Abstract]
2016	[2]				3,647,000
2017	[2]				1,057,000
2018	[2]				1,057,000
2019	[2]				0
2020	[2]				0
Thereafter	[2]				0
Total	[2]				5,761,000
Research and development, future cash payments due [Abstract]
2016	[3]				27,940,000
2017	[3]				8,652,000
2018	[3]				86,000
2019	[3]				11,000
2020	[3]				0
Thereafter	[3]				0
Total	[3]				36,689,000
Total, future minimum payments due [Abstract]
2016					31,905,000
2017					10,092,000
2018					1,506,000
2019					289,000
2020					59,000
Thereafter					0
Total					43,851,000
Loss Contingencies [Line Items]
Potential future payments					7,500,000
Litigation settlement payment		$ 4,000,000			(4,500,000)	0	$ 0
Issuance of common stock		4,500,000			$ 66,480	$ 55,924
Common stock issued (in shares) | shares					66,480,065	55,921,986
Number of shareholders lawsuits | Lawsuit					3
Options outstanding (in shares) | shares									2,095,000
Exercise price (in dollars per share) | $ / shares			$ 4.66	$ 2.39
Fees and expenses related to settlement				$ 1,100,000
Accrued litigation settlement expense					$ 4,500,000	$ 0
Litigation accounts receivable					3,500,000
Litigation setttlement					9,000,000
Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of motions filed by the company | Motion								2
Aldoxorubicin [Member]
Loss Contingencies [Line Items]
Issuance of common stock					$ 18,300,000
Minimum [Member]
Loss Contingencies [Line Items]
Legal fees to be reimbursed by insurance carrier		$ 3,500,000
Common stock issued (in shares) | shares		1,200,000
Maximum [Member]
Loss Contingencies [Line Items]
Common stock issued (in shares) | shares		1,800,000

[1] Operating leases are primarily facility lease related obligations, as well as equipment lease obligations with third party vendors. The Company recognized rent expenses of $351,075, $335,991, and $315,134 in 2015, 2014 and 2013, respectively.

[2] Employment agreements include management contracts which have been revised from time to time. The employment agreement for the Company's executive officer provide for minimum salaries, which are adjusted annually at the discretion of the Company's Compensation Committee, and in some cases provide for minimum annual bonuses, as well. New employment agreements for the Company's other executive officers are usually entered into annually or biennially.

[3] Research and development obligations relate primarily to clinical trials. All of these purchase obligations are cancelable.